Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T
- 132 Downloads
An organometallic ruthenium(II) arene compound, Ru(η6-toluene)(PTA)Cl2 (PTA = 1,3,5-triaza-7-phosphaadamantane), termed RAPTA-T, exerts promising antimetastatic properties. In this study, the effects of RAPTA-T on BRCA1-defective HCC1937 breast cancer cells have been investigated, and compared to its effects on BRCA1-competent MCF-7 breast cancer cells. RAPTA-T showed a very low cytotoxicity against both tested cells. Ruthenium is found mostly in the cytoplasmic compartment of both cells. Flow cytometric analysis reveals that the compound arrests the growth of both cells by triggering the G2/M phase that led to the induction of apoptosis. At equimolar concentrations, RAPTA-T causes much more cellular BRCA1 damage in HCC1937 than in MCF-7 cells, suppressing the expression of BRCA1 mRNA in both cell lines with the subsequent down-regulation of the BRCA1 protein. Interestingly, RAPTA-T exhibits an approximately fivefold greater ability to suppress the expression of the BRCA1 protein in HCC1937 than in MCF-7 cells. These data provide insights into the molecular mechanisms by which RAPTA-T exerts its effects on BRCA1-associated breast cancer cells.
KeywordsRuthenium complexes BRCA1 Breast cancer Cell cycle Apoptosis BRCA1 expression
This research work was supported by the National Research Council of Thailand (PHA610093S and PHA590396S), Prince of Songkla University (PHA6202079S), and the Graduate school, Prince of Songkla University. We would like to thank the Pharmaceutical Laboratory Service Center and Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University for providing research facilities.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Human and animal rights
The article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903. https://doi.org/10.1074/jbc.C000276200 CrossRefGoogle Scholar
- 29.Groessl M, Tsybin YO, Hartinger CG, Keppler BK, Dyson PJ (2010) Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. J Biol Inorg Chem 15:677–688. https://doi.org/10.1007/s00775-010-0635-0 CrossRefGoogle Scholar
- 33.Ratanaphan A, Nhukeaw T, Hongthong K, Dyson PJ (2017) Differential cytotoxicity, cellular uptake, apoptosis and inhibition of BRCA1 expression of BRCA1-defective and sporadic breast cancer cells induced by an anticancer ruthenium(II)-arene compound, RAPTA-EA1. Anticancer Agents Med Chem 17:212–220. https://doi.org/10.2174/1871520616666160404110953 CrossRefGoogle Scholar
- 34.Koch RB (1969) Fractionation of olfactory tissue homogenates. Isolation of a concentrated plasma membrane fraction. J Neurochem 16:145–157. https://doi.org/10.1111/j.1471-4159.1969.tb05933.x CrossRefGoogle Scholar
- 35.Nhukeaw T, Temboot P, Hansongnern K, Ratanaphan A (2014) Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 14:73. https://doi.org/10.1186/1471-2407-14-73 CrossRefGoogle Scholar
- 39.Chakree K, Ovatlarnporn C, Dyson PJ, Ratanaphan A (2012) Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η6-p-phenylethacrynate)Cl2(pta)]. Int J Mol Sci 13:13183–13202. https://doi.org/10.3390/ijms131013183 CrossRefGoogle Scholar
- 45.Temboot P, Lee RFS, Menin L, Patiny L, Dyson PJ, Ratanaphan A (2017) Biochemical and biophysical characterization of ruthenation of BRCA1 RING protein by RAPTA complexes and its E3 ubiquitin ligase activity. Biochem Biophys Res Commun 488:355–361. https://doi.org/10.1016/j.bbrc.2017.05.052 CrossRefGoogle Scholar
- 47.Bergamo A, Gagliardi R, Scarcia V et al (1999) In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 289:559–564Google Scholar